(FII) Lisi S.A - Ratings and Ratios
Fasteners, Implants, Assemblies, Brakes, Stapler, Prosthesis
Dividends
| Dividend Yield | 0.79% |
| Yield on Cost 5y | 1.96% |
| Yield CAGR 5y | -9.40% |
| Payout Consistency | 87.2% |
| Payout Ratio | 28.9% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 37.4% |
| Value at Risk 5%th | 54.0% |
| Relative Tail Risk | -12.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.33 |
| Alpha | 125.94 |
| CAGR/Max DD | 1.34 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.544 |
| Beta | 0.122 |
| Beta Downside | 0.333 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.50% |
| Mean DD | 9.36% |
| Median DD | 7.96% |
Description: FII Lisi S.A November 10, 2025
Lisi S.A. (ticker FII) designs and manufactures assembly- and component-level solutions for the aerospace, automotive and medical markets, operating through three dedicated segments: LISI Aerospace, LISI Automotive and LISI Medical. Its product portfolio spans high-pressure hydraulic fittings (OPTIBLIND, RIB, TYX), fasteners and structural assemblies for aircraft, cable-channel and electric-parking-brake components for cars, as well as medical implants, ancillary devices and minimally invasive surgical tools such as staplers and hip prostheses.
In FY 2023 the group reported €1.84 billion in revenue, with an operating margin of roughly 5 % and an order backlog equal to 30 % of annual sales-an indicator of resilience amid cyclical aerospace demand. The aerospace segment remains tied to the health of OEM programs at Airbus and Boeing, while the automotive side is increasingly exposed to the shift toward electric vehicles, which is driving higher demand for lightweight fastening and electronic-brake solutions. On the medical front, LISI benefits from an aging European population and the steady growth of minimally invasive procedures, a market expanding at an estimated 6 % CAGR.
For a deeper, data-driven view of LISI’s valuation dynamics, you may want to explore the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (118.6m TTM) > 0 and > 6% of Revenue (6% = 216.7m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 7.44pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.41% (prev 13.55%; Δ -3.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 323.5m > Net Income 118.6m (YES >=105%, WARN >=100%) |
| Net Debt (519.7m) to EBITDA (440.0m) ratio: 1.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (46.5m) change vs 12m ago 0.85% (target <= -2.0% for YES) |
| Gross Margin 38.13% (prev 3.32%; Δ 34.81pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 167.4% (prev 110.5%; Δ 56.86pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.95 (EBITDA TTM 440.0m / Interest Expense TTM 85.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.72
| (A) 0.16 = (Total Current Assets 1.05b - Total Current Liabilities 672.0m) / Total Assets 2.28b |
| (B) 0.02 = Retained Earnings (Balance) 38.5m / Total Assets 2.28b |
| (C) 0.12 = EBIT TTM 250.4m / Avg Total Assets 2.16b |
| (D) 0.77 = Book Value of Equity 997.0m / Total Liabilities 1.30b |
| Total Rating: 2.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.93
| 1. Piotroski 7.0pt |
| 2. FCF Yield 5.16% |
| 3. FCF Margin 3.93% |
| 4. Debt/Equity 0.79 |
| 5. Debt/Ebitda 1.18 |
| 6. ROIC - WACC (= 7.98)% |
| 7. RoE 12.25% |
| 8. Rev. Trend 94.71% |
| 9. EPS Trend -8.69% |
What is the price of FII shares?
Over the past week, the price has changed by -2.75%, over one month by +7.38%, over three months by +18.28% and over the past year by +125.17%.
Is FII a buy, sell or hold?
What are the forecasts/targets for the FII price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.6 | 8.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 61.8 | 24.8% |
FII Fundamental Data Overview December 12, 2025
Market Cap EUR = 2.23b (2.23b EUR * 1.0 EUR.EUR)
P/E Trailing = 36.1852
P/E Forward = 9.8717
P/S = 1.1546
P/B = 2.3476
Beta = 1.141
Revenue TTM = 3.61b EUR
EBIT TTM = 250.4m EUR
EBITDA TTM = 440.0m EUR
Long Term Debt = 427.5m EUR (from longTermDebt, last quarter)
Short Term Debt = 254.6m EUR (from shortTermDebt, last quarter)
Debt = 774.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 519.7m EUR (from netDebt column, last quarter)
Enterprise Value = 2.75b EUR (2.23b + Debt 774.9m - CCE 255.2m)
Interest Coverage Ratio = 2.95 (Ebit TTM 250.4m / Interest Expense TTM 85.0m)
FCF Yield = 5.16% (FCF TTM 142.1m / Enterprise Value 2.75b)
FCF Margin = 3.93% (FCF TTM 142.1m / Revenue TTM 3.61b)
Net Margin = 3.28% (Net Income TTM 118.6m / Revenue TTM 3.61b)
Gross Margin = 38.13% ((Revenue TTM 3.61b - Cost of Revenue TTM 2.23b) / Revenue TTM)
Gross Margin QoQ = 50.94% (prev 43.67%)
Tobins Q-Ratio = 1.21 (Enterprise Value 2.75b / Total Assets 2.28b)
Interest Expense / Debt = 1.70% (Interest Expense 13.1m / Debt 774.9m)
Taxrate = 25.79% (13.5m / 52.2m)
NOPAT = 185.8m (EBIT 250.4m * (1 - 25.79%))
Current Ratio = 1.56 (Total Current Assets 1.05b / Total Current Liabilities 672.0m)
Debt / Equity = 0.79 (Debt 774.9m / totalStockholderEquity, last quarter 977.6m)
Debt / EBITDA = 1.18 (Net Debt 519.7m / EBITDA 440.0m)
Debt / FCF = 3.66 (Net Debt 519.7m / FCF TTM 142.1m)
Total Stockholder Equity = 967.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.19% (Net Income 118.6m / Total Assets 2.28b)
RoE = 12.25% (Net Income TTM 118.6m / Total Stockholder Equity 967.8m)
RoCE = 17.94% (EBIT 250.4m / Capital Employed (Equity 967.8m + L.T.Debt 427.5m))
RoIC = 13.11% (NOPAT 185.8m / Invested Capital 1.42b)
WACC = 5.13% (E(2.23b)/V(3.01b) * Re(6.47%) + D(774.9m)/V(3.01b) * Rd(1.70%) * (1-Tc(0.26)))
Discount Rate = 6.47% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.42%
[DCF Debug] Terminal Value 79.36% ; FCFE base≈142.1m ; Y1≈153.3m ; Y5≈189.3m
Fair Price DCF = 72.25 (DCF Value 3.30b / Shares Outstanding 45.7m; 5y FCF grow 8.88% → 3.0% )
EPS Correlation: -8.69 | EPS CAGR: -43.90% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.71 | Revenue CAGR: 26.62% | SUE: 0.04 | # QB: 0
EPS next Year (2026-12-31): EPS=2.59 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=+29.0% | Growth Revenue=+8.6%